DPP3 and COVID-19: Given that DPP3 can cleave RAS peptides and that Ang II levels were reported to be reduced in COVID-19 patients with ARDS compared to healthy controls [81], DPP3 was examined in a European multicenter prospective cohort study of 80 critically ill COVID-19 patients.